Navigation Links
Drug shows positive responses, low side-effects in multiple myeloma
Date:12/7/2009

NEW ORLEANS ― The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

The updated data from the 17-site study focuses on patients with relapsed or resistant multiple myeloma who have received one to three prior therapies, but not the drug bortezomib, the original proteasome inhibitor.

"These findings are truly an advance for patients with multiple myeloma," said Michael Wang, M.D., associate professor, Department of Lymphoma/Myeloma at M. D. Anderson and lead author on the study. "This is an incurable, challenging disease with devastating consequences.

"While new agents are extending life expectancies, they often have adverse side effects, including severe neuropathy. Carfilzomib is showing good response rates, with an improved side effects profile," Wang said. Neuropathy is peripheral nerve pain or numbness that can become debilitating enough to halt treatment.

According to the American Cancer Society, more than 20,000 cases of multiple myeloma will be diagnosed this year in this country. More than 10,000 people will die of this disease, which is a type of blood cancer.

Better tolerated than other agents

In preclinical studies carfilzomib has been better tolerated than bortezomib, allowing consecutive day dosing and treatment over extended periods of time. Both drugs work by targeting the cell's proteasome, which destroys mutated or damaged proteins. Blocking this process causes cell death. Carfilzomib targets and binds to the proteasome differently than bortezomib.

Researchers previously observed higher response rates to carfilzomib among patients who had never been treated with bortezomib compared to those with relapsed disease following bortezomib thera
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities
2. Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients
3. New drug shows promise for those with clotting disorders: McMaster researcher
4. Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows
5. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
6. New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums
7. New Hepatitis C Treatment Shows Promise
8. Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy
9. Alcohol companies target youths with magazine ads, new study shows
10. Study shows modest improvement in advanced lung cancer overall survival rates
11. New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July ... high doses of estrogen, along with some other formulations, ... under 50, new preliminary research suggests. "There ... Beaber, a staff scientist at the Fred Hutchinson Cancer ... breast cancer risk while other formulations do not raise ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 AMTC hosts and ... a.m. and 1 p.m. in three cities on August 9. ... are invited to participate in the free auditions. , ... top actors, models, singers, dancers and comedians. Recently, AMTC grad ... went on to compete for Mrs. World in May 2014. ...
(Date:8/1/2014)... Resources and Services Administration has awarded the LSU ... an Advanced Nursing Education grant in the amount ... support training interprofessional teams of students to improve ... diverse populations with behavioral health disorders and multiple ... Anesthesia Program Director and Associate Professor of Clinical ...
(Date:8/1/2014)... The Gerontological Society of America (GSA) ... the field of aging has chosen J. ... 2014 recipient of the Distinguished Career Contribution to ... annually to an individual whose theoretical contributions have ... or have yielded original and elegant research designs ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted to ... Lewis, PT, DPT, PhD, GTC, GCS, MSG, MPA, FAPTA, ... of Aging Persons Award. , This distinguished honor is ... of rehabilitation. The awardee,s work may be in the ... may include scholarly works, books, monographs, administrative directives, or ...
Breaking Medicine News(10 mins):Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3Health News:AMTC Announces Three Upcoming Audition Sites for Upcoming Performers 2Health News:LSUHSC Nursing awarded $1 million grant to improve care for veterans 2Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2
... Ranbaxy Laboratories and Aurobinda Pharma were among some of ... UN Secretary General Kofi Annan // for their ... ,Annan complimented these companies for their efforts ... a meeting with their top executives at United Nations ...
... week of Asian countries, including China, on the global health ... substantial poultry losses and human deaths. ,"Health and ... to the meet here on July 27-28 to study how ... unprecedented in its geographical scope, spread and consequences," said a ...
... has claimed the lives of 271 people this year in ... ,Replying to the debate on cut motions in ... higher as information from interior areas had not reached the ... was "slow", he said this year 90 per cent of ...
... the ‘fat controller’ could offer new hope in treating ... of Dundee have claimed to uncover a link between ... the head of the international research team at Dundee ... of treatment for patients who suffer from these diseases. ...
... a complication, such as a hernia, within 6 months ... by HHS’ Agency// for Healthcare Research and Quality. The ... complications from obesity operations based on insurance claims data. ... among non-elderly obesity surgery patients with private insurance increased ...
... that recycling boxes are unreasonably heavy and could injure anyone ... said that any such injuries could trigger potential lawsuits. The ... could become too heavy when filled with a mixture of ... recommended weight limit. The report, which was compiled after a ...
Cached Medicine News:Health News:India to Host Asian Review Meet on Avian Flu 2Health News:Protein May Offer New Hope For Treatment Of Cystic Fibrosis 2Health News:Obesity Surgery Complication Rates Higher than Previously Thought 2
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... and reported financial results for the second quarter ... have continued to see encouraging advancements in the ... increase in estimated total prescriptions and estimated total ... Jack Lief, Arena,s President and Chief Executive Officer. ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25
... NEW YORK, June 13, 2011 Reportlinker.com ... is available in its catalogue: ... in Key SADC Countries ... aim of this research service is to ...
... 2011 Science, public health, and regulatory highlights from ... this document is designed for credentialed journalists. Release dates and ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
... The ACON PSA Semi-Quantitative Prostate Specific ... Blood/Serum/Plasma) are lateral flow tests in strip ... of Prostate Specific Antigen (PSA). The tests ... ng/mL cut-off values, and all come with ...
... Assess Functional Vision, Quality of Vision ... controls both target illumination and glare ... testing results. Day/Night testing with/without glare ... Standards and all ANSI standards. All ...
... is Recognized as a Valuable Tool ... by Early Eye Disease. Near Test ... 7 in (12.7cm x 17.78cm) Can ... Refractor,Distance Test F.A.C.T. 201: Size ...
Medicine Products: